CHMP (Committee for Medicinal Products for Human Use) recommends MS-325 for EU approval
This article was originally published in Clinica
Schering is on track to secure European market approval for its MS-325 contrast agent, after this week receiving a "positive opinion" from the EU's CHMP regarding the granting of a market authorisation. Schering and product co-developer, Epix Pharmaceuticals, are hoping the European Commission holds a similar view.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.